A new study has compared Wegovy and Zepbound head-to-head in their ability to treat obesity. People taking Eli Lilly’s ...

Weight loss drugs like Wegovy and Zepbound are getting cheaper, if you are willing to pay out of pocket for the medications.

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) ...

The popular weight loss medications produced different results in patients who participated in a trial, and here’s what researchers found.

Eli Lilly’s weight loss drug Zepbound outperformed competitor Novo Nordisk’s Wegovy, according to a clinical trial funded by Lilly. The SURMOUNT-5 trial, a Phase 3b open-label clinical trial ...

Caremark stood to receive substantial fees for the weight-loss drugs even without excluding Zepbound. Novo Nordisk and Eli Lilly have a duopoly in the booming market for weight-loss drugs ...

Published in the New England Journal of Medicine, the study followed 751 obese Americans to test the efficacy and safety of two leading weight loss drugs. Nearly 32% of Zepbound users ultimately ...

Zepbound and Wegovy were compared in a head-to-head trial to show which weight loss drug was more effective for patients. This trial consisted of 751 people in the U.S. who were overweight or ...

Eli Lilly's stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo ...

In an emailed statement to CBS News Monday, a spokesperson for Novo Nordisk, the maker of Wegovy and Ozempic, said both Wegovy and Zepbound ... the drugs aren't just about weight loss, and pointed ...